Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | EYA2 | O00167 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | MVD | P53602 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279809 | 0.83 | BHMT (0.44) | BHMTTDP1EYA2APPACE | |
| SCHEMBL1280200 | 0.80 | BHMT (0.44) | BHMTTDP1EYA2APPACE | |
| SCHEMBL1280629 | 0.77 | HSD17B10 (0.53) | BHMTTDP1ALOX15TSHRBLM | |
| SCHEMBL1280078 | 0.77 | BHMT (0.39) | BHMTTDP1EYA2APPACE | |
| SCHEMBL16608921 | 0.76 | HSD17B10 (0.56) | TDP1APPALOX15TSHRBLM | |
| SCHEMBL9525485 | 0.74 | CYP2D6 (0.50) | BHMTTDP1MVDLMNATSHR | |
| SCHEMBL2000449 | 0.73 | CA12 (0.50) | BHMTTDP1EYA2APPACE | |
| SCHEMBL1280303 | 0.73 | BHMT (0.39) | BHMTKDM4ECYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL14157523 | 0.72 | CYP2D6 (0.48) | BHMTMVDCYP2C19BLMHIF1A | |
| SCHEMBL10408722 | 0.72 | LMNA (0.64) | BHMTTDP1LMNATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065992-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2018-09-04 | — | — | US | claimed |
| EP-2627664-B1 | CYCLOSPORIN ANALOGS | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | claimed |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. | 2017-02-02 | — | — | US | claimed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | claimed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | claimed |
| EP-2627664-A1 | CYCLOSPORIN ANALOGS | Allergan, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051194-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | claimed |
| US-10065992-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-2627664-B1 | CYCLOSPORIN ANALOGS | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | BHMT 3906/4885TDP1 2386/4885EYA2 14/4885 |
| US-10065992-B2 | Cyclosporin analogs | CHP1, TSLP, PPP3R1 | BHMT 3906/4885TDP1 2386/4885EYA2 14/4885 |
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | BHMT 3906/4885TDP1 2386/4885EYA2 14/4885 |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | BHMT 3906/4885TDP1 2386/4885EYA2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.